Company: NCEL
Filing Date: 2025-03-03
Form Type: F-4/A
Source: 0001213900-25-018981
Chunk: 345

Company: NewcelX Ltd.
Filing Date: 2025-03-03
Form: F-4/A
Chunk 345
---
 |     |             |  (2,543,522 | ) |     |       |     |           |  2,053,932 |
| Commitments and Contingencies                                                         |     |               |            |     |                  |            |     |             |            |   |     |       |     |             |             |   |     |       |     |           |            |
| Shareholders’ (deficit) equity:                                                       |     |               |            |     |                  |            |     |             |            |   |     |       |     |             |             |   |     |       |     |           |            |
| Share Capital, no par value, 4,193,689 shares issued and outstanding at June 30, 2024 |     |               |  1,238,425 |     |                  |          — |     |             |          — |   |     |       |     |             |  (1,238,425 | ) |     | -Q    |     |           |          — |
| Share premium                                                                         |     |               | 62,286,200 |     |                  |          — |     |             |          — |   |     |       |     |             | (62,286,200 | ) |     | -Q    |     |           |          — |

191

Kadimastem Ltd. & NLS Pharmaceutics Ltd.
Unaudited Pro Forma Condensed Combined Balance Sheets — (Continued)

|                                                                                                                                                                                                        |     | June 30, 2024 |             |   |     |                  |             |   |     |             |             |   |     |       |     |             |            |   |     |       |     |           |             |   |
|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|:----|:--------------|------------:|:--|:----|:-----------------|------------:|:--|:----|:------------|------------:|:--|:----|:------|:----|:------------|-----------:|:--|:----|:------|:----|:----------|------------:|:--|
|                                                                                                                                                                                                        |     | Kadimastem,   
 Ltd.          |             |   |     | NLS              
 Pharmaceuticals, 
 Inc.             |             |   |     | Pro Forma   
 Adjustments 
 NLS         |             |   |     | Notes |